<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00263029</url>
  </required_header>
  <id_info>
    <org_study_id>L_8479</org_study_id>
    <nct_id>NCT00263029</nct_id>
  </id_info>
  <brief_title>Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer</brief_title>
  <acronym>PROCTFUL</acronym>
  <official_title>Pre-operative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer (PROCTFUL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of this phase II trial is to determine the efficacy and safety of the combination
      of oxaliplatin, capecitabine and radiotherapy as preoperative therapy in locally advanced
      cancers of the rectum.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (both clinical and pathological) of the primary rectal cancer observed after the chemoradiotherapy. Histologically confirmed complete resection rate (R0 rate).</measure>
    <time_frame>3-years disease- free-survival or 3-years overall survival</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events collection</measure>
    <time_frame>From the signature of the informed consent up to the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Rectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>60mg/m² as a 2-hour intravenous infusion every week for 5-6 week</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>500mg tablets and 150mg tablets. 750mg/m² bd given approximately 12 hours apart</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Planned total dose of 45-50.4Gy (with cone down) in 25-28 fractions</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG performance status score 0-1.

          -  Chemo-naïve patients.

          -  Histologically/cytologically confirmed diagnosis of rectal adenocarcinoma (clinically
             stage mT3 or mT4), either considered (1)inoperable, or (2)locally advanced, where
             histologically confirmed curative resection is considered unlikely.

          -  Evaluable measurable disease on imaging with MRI/CT to allow for response assessment.

          -  Adequate haematological, renal and liver functions as follows:

               -  ANC &gt; 3000ml

               -  Platelet count &gt; 100,000 ml

               -  Urea &amp; Serum Creatinine &lt; 1.5 X upper limit of normal value

               -  Total serum bilirubin &lt; 1.5 X upper limit of normal value

               -  ALT &amp; AST &lt; 3 X upper limit of normal value

        Exclusion Criteria:

          -  Prior chemotherapy.

          -  Documented allergy to oxaliplatin or capecitabine.

          -  Prior radiotherapy to pelvis.

          -  Previous or concurrent malignancies at other sites with the exception of basal or
             squamous cell carcinoma of the skin.

          -  Pregnant or lactating females (with negative pregnancy test documentation in
             pre-menopausal female patients).

          -  Currently participating into another clinical trial with any investigational drug in
             the previous 30 days.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iris CHAN, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2005</study_first_submitted>
  <study_first_submitted_qc>December 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2005</study_first_posted>
  <last_update_submitted>September 17, 2009</last_update_submitted>
  <last_update_submitted_qc>September 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

